Anzeige
Mehr »
Mittwoch, 23.07.2025 - Börsentäglich über 12.000 News
100% seit April - und trotzdem erst der Anfang? Kupfer wird zum Turbo-Rohstoff des Jahres!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JAZX | ISIN: SE0006371126 | Ticker-Symbol: 7V3
Stuttgart
22.07.25 | 21:54
0,247 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CANTARGIA AB Chart 1 Jahr
5-Tage-Chart
CANTARGIA AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,2450,29622.07.

Aktuelle News zur CANTARGIA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer277LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA)Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolerated...
► Artikel lesen
CANTARGIA Aktie jetzt für 0€ handeln
16.07.Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer223LUND, SE / ACCESS Newswire / July 16, 2025 / Cantargia (STO:CANTA)Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival...
► Artikel lesen
15.07.Otsuka to acquire Cantargia's CAN10 for autoimmune diseases3
15.07.Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical289Cantargia receives an upfront cash payment of USD 33 million.Cantargia is eligible to receive up to USD 580 million in development, regulatory and commercial milestone payments plus earn-out payments...
► Artikel lesen
17.06.Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans289LUND, SE / ACCESS Newswire / June 17, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced that it has entered into a loan agreement of SEK 50 million...
► Artikel lesen
17.06.Cantargia Q1 2025 slides: CAN10 advances amid funding challenges3
11.06.Cantargia's Nadunolimab Aantibody Awarded US FDA Fast Track Designation717Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further development...
► Artikel lesen
19.05.Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation224IL1RAP expression positively correlates with inflammatory markers in human atherosclerotic plaques.IL1RAP blocking antibodies inhibit endothelial activation and neutrophil adhesion induced by IL-1,...
► Artikel lesen
15.05.Bulletin from the Annual General Meeting in Cantargia AB287LUND, SWEDEN / ACCESS Newswire / May 15, 2025 / The Annual General Meeting of Cantargia (STO:CANTA) on May 15, 2025 resolved in accordance with the following:That no dividend would be paid.To discharge...
► Artikel lesen
13.05.Cantargia Publishes Interim Report for the First Quarter of 2025427LUND, SE / ACCESS Newswire / May 13, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced its interim report for the first quarter of 2025."The first...
► Artikel lesen
12.05.Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneously Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2235LUND, SE / ACCESS Newswire / May 12, 2025 / Cantargia (STO:CANTA)Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort.Model...
► Artikel lesen
06.05.Cantargia's Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors269LUND, SE / ACCESS Newswire / May 6, 2025 / Cantargia (STO:CANTA)Results published in the peer-reviewed journal Investigational New DrugsStudy in heavily pre-treated patients with solid tumor indications...
► Artikel lesen
29.04.Invitation to the Presentation of Cantargia's Interim Report for Q1 2025231LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first quarter of 2025...
► Artikel lesen
29.04.Cantargia Announces Selection of Treatment Resistant Atopic Dermatitis as Second Target Indication for CAN10219LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA)Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment optionsCAN10 targets...
► Artikel lesen
28.04.Cantargia Announces the Publication of Preclinical Data Highlighting Nadunolimab's Potential to Counteract Tumor-Driven Systemic Immunosuppression119LUND, SE / ACCESS Newswire / April 28, 2025 / Cantargia (STO:CANTA)Preclinical data shows IL1 family signals mediate systemic immune suppression.Blocking IL1RAP can overcome resistance to immune therapy...
► Artikel lesen
25.04.Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate at a Major Cancer Conference430Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironment...
► Artikel lesen
25.04.Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy at AACR370LUND, SE / ACCESS Newswire / April 25, 2025 / Cantargia (STO:CANTA)Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention...
► Artikel lesen
11.04.Cantargia Publishes Annual Report 2024326LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced that the annual report for 2024 has been published. The...
► Artikel lesen
11.04.Notice of Annual General Meeting in Cantargia AB284LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Thursday, 15 May 2025, at 15.00 CEST at Ideon...
► Artikel lesen
01.04.Cantargia appoints Morten Lind Jensen as Chief Medical Officer249LUNDE, SE / ACCESS Newswire / April 1, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced the appointment of Morten Lind Jensen, MD, PhD, as Chief...
► Artikel lesen
Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1